Evotec acquires ChemAxon software license to aid in drug discovery

By E. Janene Geiss

Philadelphia, Sept. 5 - Evotec AG and ChemAxon said Tuesday that Evotec will license ChemAxon's complete product line and announced the successful implementation of selected ChemAxon toolkits and ongoing works to roll out further capabilities across Evotec's information network.

Through the acquisition of the chemistry software company's Jchem platform, Evotec said it has built applications that enable its scientists to perform and share key drug discovery and optimization processes across all facilities directly from their workbenches, said a news release from the Hamburg, Germany, biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.